Infinity Pharmaceuticals Inc

Find Ratings Reports
INFI : NASDAQ : Health Care
$1.39 -0.01 | -0.71%
Today's Range: 1.34 - 1.41
Avg. Daily Volume: 460,500
10/21/16 - 3:59 PM ET

Financial Analysis

INFINITY PHARMACEUTICALS INC's gross profit margin for the second quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. INFINITY PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 3.36 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 36.17% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit

Income Statement Q2 FY16 Q2 FY15
Net Sales ($mil)9.474.88
EBITDA ($mil)-41.84-37.98
EBIT ($mil)-42.53-38.59
Net Income ($mil)52.99-38.43

Balance Sheet Q2 FY16 Q2 FY15
Cash & Equiv. ($mil)146.89199.48
Total Assets ($mil)187.29240.88
Total Debt ($mil)19.820.21
Equity ($mil)118.8387.26

Profitability Q2 FY16 Q2 FY15
Gross Profit Margin-441.94-778.06
EBITDA Margin-441.93-778.05
Operating Margin-449.26-790.64
Sales Turnover0.630.72
Return on Assets8.37-28.58
Return on Equity13.19-78.9
Debt Q2 FY16 Q2 FY15
Current Ratio3.563.58
Interest Expense0.310.1
Interest Coverage-138.54-385.91

Share Data Q2 FY16 Q2 FY15
Shares outstanding (mil)49.5149.17
Div / share0.00.0
Book value / share2.41.77
Institutional Own % n/a n/a
Avg Daily Volume578386.01326035.0


SELL. INFINITY PHARMACEUTICALS INC's P/E ratio indicates a significant discount compared to an average of 41.54 for the Biotechnology industry and a significant discount compared to the S&P 500 average of 24.54. For additional comparison, its price-to-book ratio of 0.60 indicates a significant discount versus the S&P 500 average of 2.72 and a significant discount versus the industry average of 9.92. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. Upon assessment of these and other key valuation criteria, INFINITY PHARMACEUTICALS INC proves to trade at a discount to investment alternatives within the industry.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
INFI 5.37 Peers 41.54   INFI NM Peers 20.57

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

INFI is trading at a significant discount to its peers.


Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

INFI's P/CF is negative making the measure meaningless.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
INFI NM Peers 32.83   INFI NM Peers 0.46

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

INFI's ratio is negative making this valuation measure meaningless.


Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

INFI's negative PEG ratio makes this valuation measure meaningless.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
INFI 0.60 Peers 9.92   INFI 118.12 Peers -0.63

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

INFI is trading at a significant discount to its peers.


Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

INFI is expected to have an earnings growth rate that significantly exceeds its peers.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
INFI 0.61 Peers 562.15   INFI -31.97 Peers 51.41

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

INFI is trading at a significant discount to its industry on this measurement.


Lower. A sales growth rate that trails the industry implies that a company is losing market share.

INFI significantly trails its peers on the basis of sales growth



Latest Stock Upgrades/Downgrades